Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome

Leukemia

Volumn 19, Issue 5, 2005, Pages 776-783

  Malcovati, L ^a   Della Porta, M G ^a   Lunghi, M ^a   Pascutto, C ^a   Vanelli, L ^a   Travaglino, E ^a   Maffioli, M ^a   Bernasconi, P ^a   Lazzarino, M ^a   Invernizzi, R ^a   Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

CD34; CD71; Flow cytometry; Immnunophenotyping; Myelodysplastic syndrome

Indexed keywords

ARTICLE; BLAST CELL; BONE MARROW CELL; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; CELL STRUCTURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ERYTHROCYTE; ERYTHROCYTE DISORDER; ERYTHROID CELL; FLOW CYTOMETRY; GRANULOCYTE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

EID: 20844445116     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403680     Document Type: Article

References (26)

1. Jacobs A. Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications. J Clin Pathol 1985; 38: 1201-1217.
2. Alessandrino EP, Amadori S, Cazzola M, Locatelli F, Mecucci C, Morra E et al. Myelodysplastic syndromes: recent advances. Haematologica 2001; 86: 1124-1157.
3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
4. Flores-Figueroa E, Gutierrez-Espindola G, Guerrero-Rivera S, Pizzuto-Chavez J, Mayani H. Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. Leuk Res 1999; 23: 385-394.
5. Cazzola M, Ponchio L, Rosti V, Farina G, Pedrotti C, Bergamaschi G. Diagnostic approach to the myelodysplastic syndromes. Leukemia 1992; 6 (Suppl 4): 19-22.
6. Bene MC, Bernier M, Castoldi G, Faure GC, Knapp W, Ludwig WD et al. Impact of immunophenotyping on management of acute leukemias. Haematologica 1999; 84: 1024-1034.
7. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998; 83: 1104-1115.
8. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-987.
9. Maynadie M, Picard F, Husson B, Chatelain B, Comet Y, Le Roux G et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002; 100: 2349-2356.
10. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887-3896.
11. Del Canizo MC, Fernandez E, Lopez A, Vidriales B, Villaron E, Arroyo J et al. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 2003; 88: 402-407.
12. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
14. Bernasconi P, Astori C, Cavigliano PM, Boni M, Malcovati L, Calatroni S et al. Cytogenetic and FISH analyses in five patients with hypoplastic bone marrow. Leukemia 2000; 14:1322-1323.
15. Anonymous. An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects Orig Artic Ser 1985; 21: 1-117.
16. Bernasconi P, Cavigliano PM, Boni M, Calatroni S, Klersy C, Giardini I et al. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 2003; 17: 2107-2112.
17. Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 2002; 16: 2078-2083.
18. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
19. Fukushima PI, Nguyen PK, O'Grady P, Stetler-Stevenson M. Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. Cytometry 1996; 26: 243-252.
20. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 1989; 52: 48-60.
21. Stelzer GT, Marti G, Hurley A, McCoy Jr P, Lovett EJ, Schwartz A. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 1997; 30: 214-230.
22. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 1878-1886.
23. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998; 34: 61-70.
24. Brando B, Barnett D, Janossy G, Mandy F, Autran B, Rothe G et al. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry 2000; 42: 327-346.
25. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87: 1286-1306.
26. Schiller GJ. Myelodysplasia-therapeutic response to novel therapy and the need for new diagnostic groups. Leukemia 2003; 17: 1183-1185.